Darolutamide plus hormone therapy before prostate cancer surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests a medicine called darolutamide taken with hormone therapy (ADT) before surgery to remove the prostate. It is for men with a high-risk prostate cancer that has not spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a high-risk prostate cancer (Gleason score 8 or higher, PSA >20, or tumor stage T3a or higher).
- Your cancer has not spread to distant organs (confirmed by CT, MRI, or bone scan).
- You plan to have your prostate removed (radical prostatectomy) with lymph node removal.
- You are able to do normal daily activities (ECOG score 0 or 1).
- You have not taken darolutamide before and are not allergic to it or hormone therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs given before surgery to shrink high-risk prostate cancer. The goal is to see if this approach can improve outcomes for patients whose cancer is aggressive but has not spread.
This study tests whether giving the drug darolutamide (with or without standard hormone therapy) before surgery helps shrink high-risk prostate cancer and reduce the chance of it coming back. If you qualify, you would receive the study treatment for a few months before your planned prostate removal surgery.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This study looks at whether combining the drug darolutamide with standard hormone therapy can help men whose prostate cancer was found in their pelvic lymph nodes after prostate removal surgery. It aims to see if this treatment helps keep the cancer from coming back.
This trial tests whether a hormone-blocking drug called darolutamide can shrink aggressive prostate cancer before surgery. Researchers will also use a special blood test to predict who benefits most from the treatment.
Hear when a new High-Risk Localized Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.